Inspira Outlines Strategic Vision and Transaction Framework for Breast Cancer Liquid Biopsy Expansion

Core Insights - Inspira Technologies is planning a strategic expansion into liquid biopsy diagnostics, aiming to preserve shareholder value while enabling future dividend distributions from its core technologies [1][2] - The proposed acquisition of a liquid biopsy platform is seen as a significant value inflection point, enhancing Inspira's capabilities in blood-based diagnostics and real-time monitoring [2][3] Company Operations - Inspira has developed the HYLA™ blood sensor platform, achieving 95% to 99% accuracy in clinical testing, and has established a dedicated blood diagnostics laboratory to support its expansion into adjacent diagnostic applications [2][3] - The company’s FDA-cleared INSPIRA™ ART100 system is currently deployed in leading U.S. hospitals, contributing to a growing commercial pipeline expected to generate revenue in 2026 [7][8] Liquid Biopsy Technology - The targeted liquid biopsy platform analyzes intact circulating tumor cells (CTCs) from blood samples, providing a more direct view of tumor characteristics over time, which could significantly improve current diagnostic practices [3][4] - Initially focusing on breast cancer, the platform is designed for routine clinical use and has shown high concordance with traditional tissue biopsies, with potential adaptability across various solid tumor indications [5][6] Transaction Structure - The acquisition is structured to allow Inspira to acquire the liquid biopsy business in exchange for up to 40% of its issued and outstanding share capital, while ensuring existing shareholders benefit from the value generated by the core respiratory business through a Contingent Value Rights (CVR) framework [13] - A concurrent equity investment of $15 million is expected to support the integration of the liquid biopsy platform and the advancement of Inspira's existing operations, with a pre-money valuation of $180 million [13][9]